Clinical Trial Update: Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) [Phase 2]

View source ↗

Summary

Phase II trial evaluating trastuzumab deruxtecan (Trastuzumab Rezetecan) alone or in combination with Adebrelimab for HER2-expressing locally advanced or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Urothelial Carcinoma, Advanced Urothelial Carcinoma | Phase 2 | Status: RECRUITING